Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo - PubMed

Affiliations

• PMID: 11016644

Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo

L M Butler et al. Cancer Res. 2000.

Abstract

Suberoylanilide hydroxamic acid (SAHA) is the prototype of a family of hybrid polar compounds that induce growth arrest in transformed cells and show promise for the treatment of cancer. SAHA induces differentiation and/or apoptosis in certain transformed cells in culture and is a potent inhibitor of histone deacetylases. In this study, we examined the effects of SAHA on the growth of human prostate cancer cells in culture and on the growth of the CWR22 human prostate xenograft in nude mice. SAHA suppressed the growth of the LNCaP, PC-3, and TSU-Pr1 cell lines at micromolar concentrations (2.5-7.5 microM). SAHA induced dose-dependent cell death in the LNCaP cells. In mice with transplanted CWR222 human prostate tumors, SAHA (25, 50, and 100 mg/kg/day) caused significant suppression of tumor growth compared with mice receiving vehicle alone; treatment with 50 mg/kg/day resulted in a 97% reduction in the mean final tumor volume compared with controls. At this dose, there was no detectable toxicity as evaluated by weight gain and necropsy examination. Increased accumulation of acetylated core histones was detected in the CWR22 tumors within 6 h of SAHA administration. SAHA induced prostate-specific antigen mRNA expression in CWR22 prostate cancer cells, resulting in higher levels of serum prostate-specific antigen than predicted from tumor volume alone. The results suggest that hydroxamic acid-based hybrid polar compounds inhibit prostate cancer cell growth and may be useful, relatively nontoxic agents for the treatment of prostate carcinoma.

Similar articles

• Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor: effects on gene expression and growth of glioma cells in vitro and in vivo.

  Yin D, Ong JM, Hu J, Desmond JC, Kawamata N, Konda BM, Black KL, Koeffler HP. Yin D, et al. Clin Cancer Res. 2007 Feb 1;13(3):1045-52. doi: 10.1158/1078-0432.CCR-06-1261. Clin Cancer Res. 2007. PMID: 17289901

• The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces growth inhibition and enhances taxol-induced cell death in breast cancer.

  Shi YK, Li ZH, Han XQ, Yi JH, Wang ZH, Hou JL, Feng CR, Fang QH, Wang HH, Zhang PF, Wang FS, Shen J, Wang P. Shi YK, et al. Cancer Chemother Pharmacol. 2010 Nov;66(6):1131-40. doi: 10.1007/s00280-010-1455-1. Epub 2010 Sep 14. Cancer Chemother Pharmacol. 2010. PMID: 20838997

• Comparative evaluation of the treatment efficacy of suberoylanilide hydroxamic acid (SAHA) and paclitaxel in ovarian cancer cell lines and primary ovarian cancer cells from patients.

  Sonnemann J, Gänge J, Pilz S, Stötzer C, Ohlinger R, Belau A, Lorenz G, Beck JF. Sonnemann J, et al. BMC Cancer. 2006 Jul 11;6:183. doi: 10.1186/1471-2407-6-183. BMC Cancer. 2006. PMID: 16834771 Free PMC article.

• Histone deacetylase inhibitors as new cancer drugs.

  Marks PA, Richon VM, Breslow R, Rifkind RA. Marks PA, et al. Curr Opin Oncol. 2001 Nov;13(6):477-83. doi: 10.1097/00001622-200111000-00010. Curr Opin Oncol. 2001. PMID: 11673688 Review.

• Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells.

  Marks PA, Richon VM, Rifkind RA. Marks PA, et al. J Natl Cancer Inst. 2000 Aug 2;92(15):1210-6. doi: 10.1093/jnci/92.15.1210. J Natl Cancer Inst. 2000. PMID: 10922406 Review.

Cited by

• Histone deacetylase inhibitors induce apoptosis in both Type I and Type II endometrial cancer cells.

  Jiang S, Dowdy SC, Meng XW, Wang Z, Jones MB, Podratz KC, Jiang SW. Jiang S, et al. Gynecol Oncol. 2007 May;105(2):493-500. doi: 10.1016/j.ygyno.2007.01.012. Epub 2007 Feb 15. Gynecol Oncol. 2007. PMID: 17303224 Free PMC article.

• Serially heterotransplanted human prostate tumours as an experimental model.

  Lopez-Barcons LA. Lopez-Barcons LA. J Cell Mol Med. 2010 Jun;14(6B):1385-95. doi: 10.1111/j.1582-4934.2009.00957.x. Epub 2009 Oct 29. J Cell Mol Med. 2010. PMID: 19874422 Free PMC article. Review.

• Immunomodulation and pharmacological strategies in the treatment of graft-versus-host disease.

  Li M, Sun K, Welniak LA, Murphy WJ. Li M, et al. Expert Opin Pharmacother. 2008 Sep;9(13):2305-16. doi: 10.1517/14656566.9.13.2305. Expert Opin Pharmacother. 2008. PMID: 18710355 Free PMC article. Review.

• HDAC-inhibitor (S)-8 disrupts HDAC6-PP1 complex prompting A375 melanoma cell growth arrest and apoptosis.

  Balliu M, Guandalini L, Romanelli MN, D'Amico M, Paoletti F. Balliu M, et al. J Cell Mol Med. 2015 Jan;19(1):143-54. doi: 10.1111/jcmm.12345. Epub 2014 Nov 6. J Cell Mol Med. 2015. PMID: 25376115 Free PMC article.

• Inhibiting HDAC1 Enhances the Anti-Cancer Effects of Statins through Downregulation of GGTase-Iβ Expression.

  Li R, Gan YH. Li R, et al. Int J Mol Sci. 2017 May 8;18(5):1010. doi: 10.3390/ijms18051010. Int J Mol Sci. 2017. PMID: 28481295 Free PMC article.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Other Literature Sources

  • The Lens - Patent Citations Database

• Medical

  • MedlinePlus Health Information